文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

作者信息

González-Padilla Daniel A, Subiela José Daniel, Villacampa-Aubá Felipe

机构信息

Department of Urology, Clínica Universidad de Navarra, Madrid, Spain.

Department or Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.

出版信息

Transl Androl Urol. 2024 Apr 30;13(4):639-642. doi: 10.21037/tau-23-563. Epub 2024 Apr 3.

DOI:10.21037/tau-23-563

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11074683/

Abstract

摘要

相似文献

[1]

Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

Transl Androl Urol. 2024-4-30

[2]

Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).

J Urol. 2023-10

[3]

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

J Urol. 2022-1

[4]

Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.

Eur Urol Focus. 2023-11

[5]

Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.

Lancet Oncol. 2020-4-29

[6]

A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.

Eur Urol Focus. 2023-5

[7]

Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.

Urol Oncol. 2023-3

[8]

Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".

World J Urol. 2022-5

[9]

Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.

J Urol. 2022-4

[10]

The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.

Urol Oncol. 2023-9

引用本文的文献

[1]

Research on the application of biomaterial-based responsive hydrogels in the tumor microenvironment.

PeerJ. 2025-7-8

本文引用的文献

[1]

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.

J Urol. 2024-4

[2]

Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).

J Urol. 2023-10

[3]

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).

Eur Urol. 2022-1

[4]

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

J Urol. 2022-1

[5]

Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.

Eur Urol Focus. 2022-3

[6]

European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.

Eur Urol. 2021-4

[7]

Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.

Clinicoecon Outcomes Res. 2020-11-23

[8]

Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia.

Urol Oncol. 2021-1

[9]

The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.

Eur Urol. 2020-12

[10]

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.

BJU Int. 2020-4-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索